Table 1.
Clinical characteristics of MARS exploratory and validation cohorts (Table 1a) and STAR*D cohort (Table 1b).
| Table 1a | ||||||||
|---|---|---|---|---|---|---|---|---|
| MARS exploratory cohort | MARS validation cohort | |||||||
| Total (n = 17) | Responders (n = 9) | Non-responders (n = 8) | p-value | Total (n = 69) | Responders (n = 33) | Non-responders (n = 36) | p-value | |
| Gender (females) | 11 | 3 | 8 | 0.01 | 33 | 13 | 20 | N.S |
| Age | 42.53 ± 12.43 | 38.11 ± 12.48 | 47.50 ± 11.02 | N.S | 47.46 ± 14.18 | 46.55 ± 15.16 | 47.39 ± 13.44 | N.S |
| HAMD baseline | 24.12 ± 6.24 | 25.78 ± 6.82 | 22.25 ± 5.34 | N.S | 25.62 ± 6.37 | 26.21 ± 5.81 | 25.08 ± 6.88 | N.S |
| HAMD 8 weeks | 12.65 ± 7.15 | 8.11 ± 4.01 | 17.75 ± 6.50 | 0.004 | 13.06 ± 6.95 | 7.70 ± 4.47 | 17.97 ± 4.87 | 9.35E−14 |
| Diagnosis | ||||||||
|
Depressive episode (ICD10 code F32) |
8 | 6 | 2 | N.S | 20 | 11 | 9 | N.S |
|
Recurrent depressive disorder (ICD10 code F33) |
9 | 3 | 6 | 49 | 22 | 27 | ||
| Treatment duration (weeks) | ||||||||
| TCAs | 0.41 ± 1.70 | 0.00 ± 0.00 | 0.88 ± 2.47 | N.S | 2.52 ± 3.46 | 2.06 ± 3.31 | 2.94 ± 3.59 | N.S |
| SSRIs | 7.59 ± 0.71 | 7.78 ± 0.67 | 7.38 ± 0.74 | N.S | 2.91 ± 3.48 | 3.79 ± 3.79 | 2.11 ± 3.01 | 0.05 |
| SNRIs | 0.59 ± 1.50 | 0.11 ± 0.33 | 1.13 ± 2.10 | N.S | 3.65 ± 3.65 | 3.18 ± 3.63 | 4.08 ± 3.66 | N.S |
| NASSAs | 1.06 ± 2.11 | 0.44 ± 0.88 | 1.75 ± 2.87 | N.S | 0.90 ± 2.14 | 1.39 ± 2.61 | 0.44 ± 1.50 | N.S |
| NARIs | 0.12 ± 0.49 | 0.22 ± 0.67 | 0.00 ± 0.00 | N.S | 0.22 ± 1.07 | 0.12 ± 0.48 | 0.31 ± 1.41 | N.S |
| SSRE | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | N.S | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | N.S |
| Other ADs | 0.24 ± 0.97 | 0.00 ± 0.00 | 0.50 ± 1.41 | N.S | 1.13 ± 2.27 | 1.00 ± 2.41 | 1.25 ± 2.17 | N.S |
| Antipsychotics | 3.47 ± 3.36 | 3.44 ± 3.09 | 3.50 ± 3.85 | N.S | 4.23 ± 3.54 | 3.73 ± 3.58 | 4.69 ± 3.50 | N.S |
| Mood stabilizers | 2.88 ± 3.04 | 2.56 ± 2.74 | 3.25 ± 3.49 | N.S | 2.78 ± 3.09 | 2.58 ± 2.86 | 2.97 ± 3.32 | N.S |
| Benzodiazepines | 3.59 ± 3.02 | 2.89 ± 3.44 | 4.38 ± 2.45 | N.S | 3.35 ± 3.07 | 3.70 ± 3.19 | 3.03 ± 2.96 | N.S |
| Sedatives | 1.29 ± 1.76 | 1.56 ± 2.24 | 1.00 ± 1.07 | N.S | 1.17 ± 1.74 | 1.06 ± 1.80 | 1.28 ± 1.70 | N.S |
| Total drug-treatment weeks | 21.24 ± 7.95 | 19.00 ± 7.47 | 23.75 ± 8.19 | N.S | 22.87 ± 7.70 | 22.61 ± 7.77 | 23.11 ± 7.75 | N.S |
| Table 1b | ||||||||
|---|---|---|---|---|---|---|---|---|
| Total (n = 44) | Responders (n = 24) | Treatment-resistants (n = 20) | p-value | |||||
| Anxious depression | 27 | 14 | 13 | N.S | ||||
| Gender | ||||||||
| Females | 23 | 14 | 9 | N.S | ||||
| Males | 21 | 10 | 11 | |||||
| Age | 48.09 ± 12.13 | 47.54 ± 13.65 | 48.75 ± 10.32 | N.S | ||||
| QIDS 0 | 17.66 ± 3.06 | 16.92 ± 3.08 | 18.55 ± 2.86 | N.S | ||||
| QIDS end | 7.95 ± 6.73 | 2.46 ± 1.89 | 14.55 ± 3.78 | 3.70E−13 | ||||
Differences were tested with Fisher test for gender and diagnosis and with t-test for age, depression scores and treatment duration (p ≤ 0.05). Data are shown as mean ± SD. N.S not significant.